Actinogen Medical outlines scientific case for Xanamem in Alzheimer’s disease ahead of pivotal trial results Proactive Investors (Australia) 01:03
The Small Cap Wrap: Actinogen Medical targets Alzheimer’s treatment gap; Percheron Phase II progress supports Edison’s 5.5-cent valuation Proactive Investors (Australia) 08:25 Wed, 05 Aug
Actinogen Medical targets Alzheimer’s treatment gap in projected $20BN market Proactive Investors (Australia) 03:30 Wed, 05 Aug
Actinogen Medical advances pivotal XanaMIA trial towards November readout - ICYMI Proactive Investors (US) 01:08 Sat, 01 Aug
Actinogen Medical keeps pivotal Alzheimer’s trial on track for November readout Proactive Investors (US) 02:09 Thu, 30 Jul
Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial Proactive Investors (US) 01:49 Fri, 24 Jul
